33 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
glucocorticoids and androgens that are under the control of ACTH. Data in a Phase 1 healthy volunteer study demonstrated pharmacologic proof-of-concept
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
Exposure in Patients with Carcinoid Syndrome was Consistent with Expectations from Healthy Volunteers Healthy volunteer data is from paltusotine … -dose, 80 mg trough, and 80 mg post-dose, respectively. Healthy Volunteer Carcinoid Syndrome Patients
Paltusotine was Well-Tolerated with No Severe
8-K
EX-99.1
ewvbbutw6q 2zs4w
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
palgrtkd4ua92qo
12 Aug 22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:41am
8-K
EX-99.1
sbotb0
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
7wjjal5be41rwoomu1b
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
8-K
EX-99.2
rj09ms8hzsb2pa
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
tw8i1qtvi75dug9hs0
17 Mar 22
Other Events
6:22pm
8-K
EX-99.1
7i62vrckmakyvy5v
5 Nov 21
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.2
bio46
10 Aug 21
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:05pm
8-K
EX-99.1
w3pw2eg4zo
6 May 21
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results
4:01pm
424B5
p1n h4wau
8 Apr 21
Prospectus supplement for primary offering
4:07pm